These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 31889520)

  • 1. Corrigendum to "HMGB1 and SEPP1 as predictors of hepatocellular carcinoma in patients with viral C hepatitis: Effect of DAAs" [Clin. Biochem. 70 (2019) 8-13].
    Rizk NI; Sallam AM; El-Ansary AR; El-Mesallamy HO
    Clin Biochem; 2020 Feb; 76():50. PubMed ID: 31889520
    [No Abstract]   [Full Text] [Related]  

  • 2. HMGB1 and SEPP1 as predictors of hepatocellular carcinoma in patients with viral C hepatitis: Effect of DAAs.
    Rizk NI; Sallam AM; El-Ansary AR; El-Mesallamy HO
    Clin Biochem; 2019 Aug; 70():8-13. PubMed ID: 31158358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
    Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
    J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
    Ida H; Hagiwara S; Kono M; Minami T; Chishina H; Arizumi T; Takita M; Yada N; Minami Y; Ueshima K; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):565-573. PubMed ID: 29040989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hepatitis C-related hepatocellular carcinoma and the treatment with direct-acting antiviral agents].
    Liu X; Gao YH; Niu JQ
    Zhonghua Gan Zang Bing Za Zhi; 2017 Dec; 25(12):944-947. PubMed ID: 29325299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B virus X protein stimulates high mobility group box 1 secretion and enhances hepatocellular carcinoma metastasis.
    Chen S; Dong Z; Yang P; Wang X; Jin G; Yu H; Chen L; Li L; Tang L; Bai S; Yan H; Shen F; Cong W; Wen W; Wang H
    Cancer Lett; 2017 May; 394():22-32. PubMed ID: 28216372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular Carcinoma Occurrence/Recurrence after Direct-Acting Antivirals for Hepatitis C in Egyptian Cohort: Single-Center Experience.
    Lashen SA; Shamseya MM; Madkour MA
    Dig Dis; 2019; 37(6):488-497. PubMed ID: 31216532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
    Adhoute X; Penaranda G; Raoul JL; Sellier F; Castellani P; Oules V; Perrier H; Lefolgoc G; Pol B; Campanile M; Bayle O; Beaurain P; Monnet O; Bourlière M
    Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):368-375. PubMed ID: 29384796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Impression of direct-acting antiviral agents in the treatment of recurrent hepatocellular carcinoma related to chronic hepatitis C].
    Zhang XH; Gao ZL
    Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):179-183. PubMed ID: 29804390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HMGB1 Promotes Hepatitis C Virus Replication by Interaction with Stem-Loop 4 in the Viral 5' Untranslated Region.
    Yu R; Yang D; Lei S; Wang X; Meng X; Xue B; Zhu H
    J Virol; 2015 Dec; 90(5):2332-44. PubMed ID: 26656705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the direct-acting antiviral agents (DAAs) on chronic hepatitis C in Sardinian patients with transfusion-dependent Thalassemia major.
    Ponti ML; Comitini F; Murgia D; Ganga R; Canu R; Dessì C; Foschini ML; Leoni G; Morittu M; Perra M; Pilia MP; Casini MR; Zappu A; Origa R
    Dig Liver Dis; 2019 Apr; 51(4):561-567. PubMed ID: 30658940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus.
    Abdelaziz AO; Nabil MM; Abdelmaksoud AH; Shousha HI; Cordie AA; Hassan EM; Omran DA; Leithy R; Elbaz TM
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):39-43. PubMed ID: 29064851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C.
    Chu PS; Nakamoto N; Taniki N; Ojiro K; Amiya T; Makita Y; Murata H; Yamaguchi A; Shiba S; Miyake R; Katayama T; Ugamura A; Ikura A; Takeda K; Ebinuma H; Saito H; Kanai T
    PLoS One; 2017; 12(6):e0179096. PubMed ID: 28617830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma.
    Tong MJ; Blatt LM; Kao JH; Cheng JT; Corey WG
    World J Gastroenterol; 2006 Nov; 12(41):6620-6. PubMed ID: 17075974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential role of High mobility group box 1 in hepatocellular carcinoma.
    Zhou RR; Kuang XY; Huang Y; Li N; Zou MX; Tang DL; Fan XG
    Cell Adh Migr; 2014; 8(5):493-8. PubMed ID: 25482616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents.
    Lin M; Kramer J; White D; Cao Y; Tavakoli-Tabasi S; Madu S; Smith D; Asch SM; El-Serag HB; Kanwal F
    Aliment Pharmacol Ther; 2017 Nov; 46(10):992-1000. PubMed ID: 28949020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.
    Nagata H; Nakagawa M; Asahina Y; Sato A; Asano Y; Tsunoda T; Miyoshi M; Kaneko S; Otani S; Kawai-Kitahata F; Murakawa M; Nitta S; Itsui Y; Azuma S; Kakinuma S; Nouchi T; Sakai H; Tomita M; Watanabe M;
    J Hepatol; 2017 Nov; 67(5):933-939. PubMed ID: 28627363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis.
    Ioannou GN; Splan MF; Weiss NS; McDonald GB; Beretta L; Lee SP
    Clin Gastroenterol Hepatol; 2007 Aug; 5(8):938-45, 945.e1-4. PubMed ID: 17509946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Implication of the Relationship Between High Mobility Group Box-1 and Tumor Differentiation in Hepatocellular Carcinoma.
    Ando K; Sakoda M; Ueno S; Hiwatashi K; Iino S; Minami K; Kawasaki Y; Hashiguchi M; Tanoue K; Mataki Y; Kurahara H; Maemura K; Shinchi H; Natsugoe S
    Anticancer Res; 2018 Jun; 38(6):3411-3418. PubMed ID: 29848691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after Direct Acting Antivirals: multicenter analysis.
    Hiraoka A; Kumada T; Ogawa C; Kariyama K; Morita M; Nouso K; Toyoda H; Tada T; Ochi M; Murakami T; Izumoto H; Ueki H; Kitahata S; Aibiki T; Okudaira T; Yamago H; Iwasaki R; Tomida H; Miyamoto Y; Mori K; Miyata H; Tsubouchi E; Kishida M; Ninomiya T; Michitaka K
    J Gastroenterol Hepatol; 2019 Feb; 34(2):436-441. PubMed ID: 29996177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.